- Home
- KRYS
KRYS
Krystal Biotech Inc.
as of 02-13-2026 3:44pm EST
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | 7.8B | IPO Year: | 2017 |
| Target Price: | $257.45 | AVG Volume (30 days): | 249.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 6.66 | EPS Growth: | 275.72 |
| 52 Week Low/High: | $122.80 - $295.98 | Next Earning Date: | 02-17-2026 |
| Revenue: | $373,164,000 | Revenue Growth: | 54.51% |
| Revenue Growth (this year): | 36.1% | Revenue Growth (next year): | 42.21% |
| P/E Ratio: | 41.50 | Index: | N/A |
| Free Cash Flow: | 165.6M | FCF Growth: | +185.19% |
AI-Powered KRYS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Krystal Biotech Inc. (KRYS)
Chief Accounting Officer
Avg Cost/Share
$273.80
Shares
12,500
Total Value
$3,401,705.16
Owned After
29,818
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Romano Kathryn | KRYS | Chief Accounting Officer | Feb 9, 2026 | Sell | $273.80 | 12,500 | $3,401,705.16 | 29,818 |
Compare KRYS vs Leading Stocks
See how KRYS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KRYS Krystal Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.